PIMAVANSERIN: HITTING THE SPOT IN HALLUCINATION AND DELUSION OF PARKINSONâ€™S DISEASE
Dick B. S. Brashier, Prashant Mishra*, Htet Wai Moe, Kedar G. Bandekar and Neha Akhoon
Parkinsonâ€™s disease psychosis (PDP) is a vivid suffering with high morbidity and mortality rate in Parkinsonâ€™s disease patients. After a long era of precautious atypical antipsychotic treatments, the first and safer drug Pimavanserin was recently approved by FDA. Pimavanserin is a highly selective 5-HT2A receptor inverse agonist. It showed high level of safety and tolerability with effective symptom control of Parkinsonâ€™s disease psychosis. The most prominent benefit of Pimavanserin is avoidance of motoric and non-motoric side effects. Pimavanserin brings meaningful hopes to Parkinsonâ€™s disease psychotic patients but further voluminous research needs to be engaged in the treatment of PDP.
Keywords: Parkinsonâ€™s disease psychosis, Pimavanserin, 5-HT2A
[Full Text Article]